What question did this study set out to answer?

The aim is to evaluate the cost-effectiveness of atezolizumab plus bevacizumab compared to other therapies in Malaysia.

April 28, 2026Open Access

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Key Points

The aim is to evaluate the cost-effectiveness of atezolizumab plus bevacizumab compared to other therapies in Malaysia.
Cost-effectiveness analysis comparing atezolizumab plus bevacizumab to lenvatinib and sorafenib.
Evaluation across various willingness-to-pay values, based on Malaysia's GDP per capita.
Atezolizumab plus bevacizumab is cost-effective at WTP values of one to three times Malaysia's GDP per capita.
Findings support the potential for improved health outcomes with expanded funding for atezolizumab plus bevacizumab.

Abstract

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Yoke Fui Wong

Rosmawati Mohamed

Audi Adawiah Sulaiman Shah

Journals

Journal of Medical Economics

Actions

Institutions

University of Utah

Chulalongkorn University

National University of Malaysia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study